Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIST: Indacaterol vs Salmeterol in COPD
NCT00821093Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Forced Expiratory Volume in 1 Second Standardized Area Under the Curve at Week 12. Started Jan 2009; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00821093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00821093.